SLU-PP-332 + 5-Amino-1MQ (Capsule)

SLU-PP-332 + 5-Amino-1MQ Capsule

A synergistic metabolic blend combining ERR agonism and NNMT inhibition for comprehensive fat loss and metabolic health.

100% 50% · t½ Time → Serum level
Molecular Weight Not specified
Half-Life Varies
Typical Dose One capsule
Cycle Length 8–12 weeks

Description

This synergistic metabolic blend combines SLU-PP-332 (an ERRalpha/gamma agonist that mimics endurance exercise at the molecular level) with 5-Amino-1MQ (an NNMT inhibitor that raises cellular NAD+ levels), creating a comprehensive approach to metabolic optimization through two distinct but complementary pathways. SLU-PP-332 activates the ERR transcription factor network to drive mitochondrial biogenesis and fat oxidation, while 5-Amino-1MQ inhibits NNMT to raise NAD+ and activate the AMPK/sirtuin axis. Together, these two compounds address metabolic health from both the transcriptional level (ERR agonism programming cells to burn more fat) and the coenzyme level (NAD+ supporting the enzymatic machinery of fat oxidation). This combination is particularly relevant for individuals seeking fat loss, improved metabolic health, and mitochondrial optimization without appetite suppression or stimulant effects. Both compounds have demonstrated meaningful metabolic improvements in preclinical models, and their mechanisms are non-overlapping, suggesting additive or synergistic effects.

Key Characteristics

Molecular Formula

Molecular Formula

Half-Life

Administration Routes

Oral capsule

Typical Dose

One capsule (per prescriber guidance)

Frequency

Daily

Investigated Benefits

* Benefits based on preclinical/animal research unless otherwise noted.

Mechanism of Action

“A synergistic metabolic blend combining ERR agonism and NNMT inhibition for comprehensive fat loss and metabolic health.”

SLU-PP-332 activates ERRalpha and ERRgamma nuclear receptors, which regulate hundreds of genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. This creates a transcriptional program that increases mitochondrial density, enhances fat burning capacity, and promotes metabolically active muscle fiber types — essentially the molecular signature of endurance exercise adaptation. 5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that depletes NAD+ and SAM in adipose tissue. By inhibiting NNMT, 5-Amino-1MQ raises cellular NAD+ levels, which activates SIRT1 and other sirtuins that regulate fat storage gene expression, and activates AMPK, which promotes fatty acid oxidation and inhibits lipogenesis. The combination provides complementary metabolic activation: SLU-PP-332 drives the transcriptional machinery of fat oxidation, while 5-Amino-1MQ provides the coenzyme substrate (NAD+) and signaling molecule (AMPK) needed to execute that program efficiently.

Administration Routes

Oral capsule

Key Characteristics

Typical Dose

One capsule (per prescriber guidance)

Frequency

Daily

Cycle Length

8–12 weeks

Administration

Oral capsule

Protocol Notes

Take in the morning with or without food. Can be combined with exercise for additive metabolic effects.

Reconstitution Guide

Storage Information

Store at room temperature, away from light and moisture.

Quality & Sourcing Standards

When sourcing SLU-PP-332 + 5-Amino-1MQ (Capsule) for research purposes, the following quality benchmarks should be verified before use.

Purity:

>98% (verified by HPLC)

Certificate of Analysis (COA):

Must be provided by supplier

Endotoxin Testing:

<0.1 EU/mg (prevents bacterial contamination)

GMP Compliance:

Manufactured in cGMP-certified facility

Third-Party Testing:

Independent lab verification preferred

Storage Information

Store at room temperature, away from light and moisture.

FDA Disclaimer

The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.

Research Highlights

1

Both components demonstrated metabolic benefits in animal models

2

Complementary mechanisms provide synergistic metabolic activation

3

NNMT inhibition and ERR agonism target distinct but complementary pathways

Compatible Peptides

Peptides commonly used alongside SLU-PP-332 + 5-Amino-1MQ (Capsule) for synergistic effects.

 

NAD+

The essential coenzyme for cellular energy production and DNA repair that declines significantly with age.

BAM-15 + SLU-PP-332 + C15 (Capsule)

A triple metabolic complex targeting mitochondrial uncoupling, ERR agonism, and cellular aging for comprehensive metabolic optimization.

Quick Reference

Category

Metabolic & Weight
 

Status

Research Only
 

Dose

One capsule (per prescriber guidance)
 

Frequency

Daily
 

Cycle

8–12 weeks